Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA nod for Aurobindo's OTC cetirizine solution

This article was originally published in Scrip

Executive Summary

Aurobindo Pharma has received final US FDA approval for cetirizine hydrochloride solution 1mg/mL (OTC), a generic version of McNeil Consumer Healthcare Children's Zyrtec oral solution 1 mg/mL and children's Zyrtec oral solution 1 mg/mL. The product is used for the relief of symptoms associated with seasonal allergic rhinitis in adults and children over two years of age, and certain other indications including relief from itching due to hives. Aurobindo expects to launch the product shortly. The company has a total of 83 ANDA approvals and 28 tentative approvals from the FDA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC006744

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel